|
Munich Biotech AG has announced details of results presented during a recent congress of clinical investigators reporting on results of Phase I trials of MBT-0206 in cancer patients. New results have indicated that patients continuing with MBT-0206 beyond the trial period on compassionate grounds show quality of life improvements stabilization and in some cases tumor regression. In addition neither increasing cytotoxic side-effects nor drug resistance were recorded. This profile differentiates MBT-0206 a novel anti-neovascular therapy from most other chemotherapies.
|